Georgia’s Medical Cannabis Commission Oversight Committee must decide how the state would conduct required testing of cannabis oil before the rollout of the state’s medical marijuana program.
The committee was supposed to recommend a process and plan for providing accredited lab testing and labeling of the medical cannabis oil by Aug. 1, according to law, but the program launch has faced delays.
Rep. Micah Gravley, R–Douglasville, said the delays were caused by “unforeseen circumstances,” but cannabis trade advocates said the pandemic, understaffing and underfunding were to blame.
– Read the entire article at The Gazette.
